China: A New Biopharma Model Emerging
Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry. Napoleon once said: “China is a sleeping giant. Let her sleep, for…
Address: Guilinyang Develops Area, Haikou, Hainan province, P.R.China 571127
Tel: +86 898 6571 8261
Hainan Yishun Pharmaceutical Co,. Ltd is a modern large pharmaceutical enterprise, which is established in Jun 6, 2003, with a registered capital of 50 million RMB (about 7.8 million dollars) and fixed asserts of 100 million RMB (about 15.7 million dollars). Company is located in Guilinyang Develops Area, Haikou, Hainan province, P.R.China. The plant area is more than 12,000 square meters, with a staff of more than 200. There are several production lines: powder for injection, new-type solid dosage form, APIs, small capacity injection and lyophilized powder for injection. All the production lines, staff and facility are organized and built strictly by GMP standard, and pass through and obtain new version SFDA-GMP certificate. On the aspect of quality control and quality assurance, we start with a high standard to build new plants, to introduce advanced production equipments, to be equipped with state-level drug quality testing instruments. All the efforts we make are to establish a comprehensive quality control and quality assurance system to supervise every link of drug production, sale and recall to ensure product quality. The whole process is in strict accordance with GMP requirements to implement and manage.
For overseas market, we will focus on promoting products of lyophilized powder for injection and sterile powder for injection. There is a products catalog available for international registration and sale. The overseas target markets of the company are Southeast Asia, Africa and Latin America. The company is looking for long-term partners and agents to create business opportunities and to achieve a win-win situation.
Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry. Napoleon once said: “China is a sleeping giant. Let her sleep, for…
Chinese ecommerce behemoths Alibaba and JD.com are being used to buy and sell tens of thousands of prescription medicines, skirting regulations in what is a legal grey area. According to…
Andy A. Liu, CEO of CW Data Technologies, a joint venture between WuXi AppTec and China Electronics Data Corporation at the intersection of Big Data and healthcare, discusses emerging trends…
Simon Yam, managing director of Geodis Greater China, shares the importance of the Greater China region to Geodis globally, the region’s strong performance and growth, the strategic importance of the…
Gene Shigekawa, managing partner of MAZ World, shares their recent move to the Hong Kong Science and Technology Park (HKSTP) in 2017, the revolutionary ostrich-derived antibody they hope to further…
Louis Sze, CEO of Personal Surgical Modelling, an exciting Hong Kong start-up in the 3D printing medical technology field, shares the company’s achievements over the past few years, his insights…
K P Tsang, president of the Hong Kong Alliance for Rare Diseases (HKARD), shares the challenges faced by patients with rare diseases and their caregivers in Hong Kong, the areas…
Dr. Harley Seyedin, president of AmCham South China, talks up increasing connectivity in the region, competition and collaboration between the Greater Bay Area cities, and their potential for international life…
Rupert Mok, a veteran of the Hong Kong medtech industry, discusses regulatory alignment between Hong Kong and mainland China, opportunities for collaboration, the consumer ‘wearable’ space, and the state of…
This week, China has fast-tracked approval for 48 “much-needed medicines.” Regulators gave special consideration to new treatments for rare diseases as well as drugs that target serious, life-threatening illnesses, like cancer. Authorities…
One of China’s biggest vaccine manufacturers was found to have falsified rabies vaccine records causing nationwide parenting chaos. Executives from China’s second largest pharmaceutical company, ChangSheng biotechnology (Changsheng literally translates…
Dr. Qiu, could you please introduce your company, H-Guard, to our international readers? “It is clear that our efforts and investments over the past five years have paid off. Just…
See our Cookie Privacy Policy Here
